Bartha et al., Influence des facteurs héréditaires du VIH sur la progression de l’infection VIH
Influence des facteurs héréditaires du VIH sur la progression de l’infection VIH.   PLoS Computational Biology L’infection VIH chez les personnes qui ne sont pas sous traitement anti-VIH progresse à des rythmes différents. Ceci se manifeste entre autres par la durée entre la contamination et l’apparition du SIDA qui varie, chez les séropositifs sans traitement, […]
Dolutegravir containing ART regimens in HIV-1-infected pregnant women and their infants
Efficacy and safety of dolutegravir containing ART regimens in HIV-1-infected pregnant women and their infants Due to actual reasons, the press release of this week summarizes the latest news of the IMPACT 2010 study, investigating the efficacy and safety of dolutegravir containing antiretroviral therapy in pregnant women. So far, productive toxicology studies and other data […]
Santos et al., Effectiveness of boosted PI-based therapy in Europe
Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe.   HIV Medicine Santos et al. on behalf of the EuroSIDA study group aimed to evaluate the long-term effectiveness of different protease inhibitor (PI) containing regimens initiated at various stages during participants’ antiretroviral therapy (ART) history and the factors associated with virological failure (VF), […]
Kamal et al., Attitudine delle persone con infezione HIV rispetto alla co-medicazione
Attitudine delle persone con infezione HIV rispetto alla co-medicazione in paragone alla terapia per l’HIV.   HIV Medicine La maggioranza delle persone sieropositive assume i medicamenti per l’HIV in modo coscienzioso e con una buona aderenza terapeutica. Ma qual’è l’aderenza terapeutica rispetto i medicamenti concomitanti (co-medicazione), come ad esempio i medicamenti per l’ipertensione arteriosa, il diabete […]
Kamal et al., Meinung von HIV-positiven Personen gegenüber ihren Co-Medikamenten
Meinung von HIV-positiven Personen gegenüber ihren Co-Medikamenten im Vergleich zu ihren HIV-Medikamenten.   HIV Medicine Die meisten HIV-positiven Menschen nehmen ihre HIV-Medikamente sehr zuverlässig ein und zeigen somit eine gute Therapieadhärenz. Doch wie zuverlässig werden von den Betroffenen nicht-HIV Medikamente (sogenannte Co-Medikamente) wie Blutdrucktabetten, Diabetesmedikamente und Cholesterinsenker eingenommen? Um dieser Frage nachzugehen, haben Forscher aus […]
Raisaro et al., Privacy-enhancing technologies for genomic data
Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study.   Journal of Biomedical Informatics Raisaro et al. aimed to describe end-users’ perception of genome privacy and their attitude toward the use of sophisticated PETs in an operational clinical setting. The participating physicians had […]
Kamal et al., Attitude des personnes atteintes du VIH envers leur co-médication
Attitude des personnes atteintes du VIH envers leur co-médication comparé à leur médication anti-VIH.   HIV Medicine La plupart des séropositifs prennent leur médicaments anti-VIH très consciencieusement et ont une bonne observance thérapeutique. Mais quelle est leur observance thérapeutique envers les médicaments non-VIH (appelés co-médicaments) comme par exemple comprimés anti-hypertension, médicaments contre le diabète et […]
Anderegg et al., Immunodeficiency at cART Initiation
Global trends in CD4 cell count at the start of antiretroviral therapy: Collaborative Study of Treatment Programs. Â Â Clinical Infectious Disease Anderegg et al. on behalf of IeDEA and COHERE examined global trends in CD4 cell counts at combination antiretroviral therapy (cART) initiation among adults from low-income (LICs), lower-middle-income (LMICs), upper-middle-income (UMICs), and high-income (HICs) […]
Young et al., Pill count and clinical outcome in HIV
Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection.   HIV Medicine Young et al. assessed whether the one-pill combination of efavirenz, emtricitabine and tenofovir reduces the risk of AIDS or death in treatment-naïve HIV-infected patients starting ART compared with two- or three-pill formulations of the same regimen. The analysis was based […]
Strouvelle, Braun et al., Effect of pIFN-α on total HIV-1 DNA load
No effect of pegylated interferon-alpha on total HIV-1 DNA load in HIV-1/HCV coinfected patients.   Journal of Infectious Diseases Strouvelle, Braun et al. aimed to examine the effect of pegylated interferon-alpha (pIFN-α) treatment in reducing total HIV-1 DNA levels in 40 HIV-1/hepatitis C virus (HCV-) coinfected patients from the Swiss HIV Cohort Study and the Zurich […]